CORD-19:c654596857bce9cdd64ffc51842048643107348c / 358054-358340 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T3073","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"TextSentencer_T3074","span":{"begin":138,"end":286},"obj":"Sentence"},{"id":"T82108","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"T85010","span":{"begin":138,"end":286},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Antimicrobial susceptibility of Proteus mirabilis clinical isolates producing extended spectrum beta-lactamases (ESBLs) PM111 Objectives: The aim of the present study was to determine in vitro susceptibility to antimicrobials of Proteus mirabilis isolated from urinary tract infections."}

{"project":"Epistemic_Statements","denotations":[{"id":"T467","span":{"begin":0,"end":286},"obj":"Epistemic_statement"}],"text":"Antimicrobial susceptibility of Proteus mirabilis clinical isolates producing extended spectrum beta-lactamases (ESBLs) PM111 Objectives: The aim of the present study was to determine in vitro susceptibility to antimicrobials of Proteus mirabilis isolated from urinary tract infections."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T73","span":{"begin":0,"end":137},"obj":"Sentence"},{"id":"T74","span":{"begin":138,"end":286},"obj":"Sentence"}],"text":"Antimicrobial susceptibility of Proteus mirabilis clinical isolates producing extended spectrum beta-lactamases (ESBLs) PM111 Objectives: The aim of the present study was to determine in vitro susceptibility to antimicrobials of Proteus mirabilis isolated from urinary tract infections."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T762","span":{"begin":261,"end":285},"obj":"Phenotype"}],"attributes":[{"id":"A762","pred":"hp_id","subj":"T762","obj":"http://purl.obolibrary.org/obo/HP_0000010"}],"text":"Antimicrobial susceptibility of Proteus mirabilis clinical isolates producing extended spectrum beta-lactamases (ESBLs) PM111 Objectives: The aim of the present study was to determine in vitro susceptibility to antimicrobials of Proteus mirabilis isolated from urinary tract infections."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1767","span":{"begin":261,"end":285},"obj":"Disease"},{"id":"T27471","span":{"begin":261,"end":285},"obj":"Disease"}],"attributes":[{"id":"A1767","pred":"mondo_id","subj":"T1767","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A1768","pred":"mondo_id","subj":"T1767","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"},{"id":"A54057","pred":"mondo_id","subj":"T27471","obj":"http://purl.obolibrary.org/obo/MONDO_0001650"},{"id":"A63432","pred":"mondo_id","subj":"T27471","obj":"http://purl.obolibrary.org/obo/MONDO_0005247"}],"text":"Antimicrobial susceptibility of Proteus mirabilis clinical isolates producing extended spectrum beta-lactamases (ESBLs) PM111 Objectives: The aim of the present study was to determine in vitro susceptibility to antimicrobials of Proteus mirabilis isolated from urinary tract infections."}